ArticleAlpha psychiatry2022
Optical Coherence Tomography Angiography in Schizophrenia.
Article in Alpha psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Retina as a potential biomarker in schizophrenia spectrum disorders: a systematic review and meta-analysis of optical coherence tomography and electroretinography.Molecular psychiatry · 2024Pooled it
- Retinal biomarkers in schizophrenia spectrum disorders: evidence and implications for the neurodevelopmental and neurodegenerative models.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of this study is to investigate the retinovascular structure of schizophrenia patients using optical coherence tomography angiography (OCTA). Methods: 47 eyes of schizophrenia patients were compared with 50 eyes of demographically matched healthy controls in terms of OCTA measurements. Schizophrenia patients were evaluated in two groups as short-term (≤ 5years) and long-term (> 5years) according to the time elapsed after the diagnosis of schizophrenia. Results: Schizophrenia patients showed overall thinning of retinal nerve fiber layer and macula, and lower vessel density (VD) compared to controls. The results were significant for thickness measurements of general macula and for VD in specific areas ( Conclusions: These findings suggest that schizophrenia may be a neurodegenerative disease with progressive microvascular involvement over the years, and that OCTA has the potential to be a useful tool in detecting retinovascular changes in patients with schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.